Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB.

Published byΜάρκος Κωνσταντόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB."— Presentation transcript:

1 (A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB tumors with all other subtypes. (A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB tumors with all other subtypes. Number of tumors of each subtype is indicated at the bottom. (B) Kaplan–Meier plot of relapse-free survival (RFS) probability of lumB breast cancer patients separated according to LATS2 expression levels (n = 407, KM-plotter [Györffy et al, 2010]). Noa Furth et al. LSA 2018;1:e © 2018 Furth et al.

Download ppt "(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB."

Similar presentations

Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.

Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.
Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < 0.0001(Log-rank) a Months Low gene expression.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.
P

P
A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.

A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.
Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR.

Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR.
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716

A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716
C Supplemental Figure S2.. C Supplemental Figure S2.

C Supplemental Figure S2.. C Supplemental Figure S2.
Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.
Hallett, et al., - Supplementary Figure 1

Hallett, et al., - Supplementary Figure 1
High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.

High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.
a b SUM149PT Motility Invasion C V C V

a b SUM149PT Motility Invasion C V C V
سرطان الثدي Breast Cancer

سرطان الثدي Breast Cancer
A B C Supplementary figure S7

A B C Supplementary figure S7
Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.
Prognostic significance of DDB2 in ovarian cancer.

Prognostic significance of DDB2 in ovarian cancer.
(A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza) for 4 d. (A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza)

(A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza) for 4 d. (A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza)
PPARγ signaling correlates with LATS2 in human and mouse tumors and promotes cell death in a LATS2-dependent manner. PPARγ signaling correlates with LATS2.

PPARγ signaling correlates with LATS2 in human and mouse tumors and promotes cell death in a LATS2-dependent manner. PPARγ signaling correlates with LATS2.
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Similar presentations

Ads by Google